In breast, prostate, and esophageal carcinomas, the expression of TLR3 correlates with tumor aggressiveness and poor clinical outcomes related to TLR3’s ability to promote cancer stem cell survival, cell invasion, and inflammation (Sato et al, 2009; Jia et al, 2015; Bugge et al, 2017). Here, TLR3 is linked to neoplasm.